公司資料
Travere Therapeutics 股價、新聞與催化劑
- 股票代碼:
- TVTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
65.22 USD (-0.75%)
收盤價
最後更新: 2026年8月24日
3.99B USD
市值
股價為何變動
As of Aug 24, 2026, TVTX closed down 0.75% at $65.22. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Travere Therapeutics is a rare-disease company with a focus on kidney and hepatology programs. Its business combines commercial execution with pipeline development in hard-to-treat diseases.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Travere sits in specialty biopharma.
商業模式特徵
The model is driven by product adoption, label expansion, and development in additional rare disease settings.
生技產業定位
Travere is a specialty-rare-disease name whose stock can move on both commercial traction and pipeline progress.
未來催化劑
- Travere's catalysts are FILSPARI execution in IgA nephropathy and any FSGS or label-expansion step that widens the renal franchise. The company improves when the nephrology story keeps compounding.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。